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Billing guidelines from HPCSA 
needed
To the Editor: I noted with concern an item from the Health 
Professions Council of South Africa (HPCSA) website, ‘Do 
not be over-charged by your health practitioner’ (13 October 
2006), by Adv. B Mkhize. After the findings of the Competition 
Commission, practitioners were left out in the cold as to which 
fees to charge. As we are all aware, the old Scale of Benefits, 
now the National Health Reference Price List (NHRPL), has 
always been a bone of contention. Overwhelmingly promoted 
by medical insurance companies, it has never been accepted by 
all doctors. Understandably so, because no other profession has 
its billing protocols prescribed by an outside, totally unrelated 
organisation. Furthermore, surely patients should only be 
informed if ‘medical aid rates’, i.e. not normal fees as prescribed 
by our peers, will be charged? More than 80% of anaesthesiolo-
gists registered with the South African Society of Anaesthetists 
charge above NHRPL rates, which the HPCSA deems to be the 
benchmark. Billing practices cause much confusion and embar-
rassment for doctors and patients, at times gleefully spurred 
on by medical insurers. It behoves the HPCSA, in consultation 
with medical practitioners (not medical aids, not government), 
to set clear and unequivocal guidelines, or otherwise to remove 
itself from the field.
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1 Castanea Place 
Florida Glen 
1709
legro@iafrica.com
Controlled trials – thinking the 
unthinkable?
To the Editor: I read your editorial in the January issue of the 
Journall with pleasure.
In 1996, when the sacred cows of controlled clinical trials 
were regarded as unassailable, I was Editor of CME. At that 
time I published an article by Dr Bernard Brom entitled 
‘Controlled clinical trials and anecdotes’2 in which he did the 
unthinkable – he suggested that controlled trials were not 
always the absolute final word on drug or other therapeutic 
usage. He tried to debunk the mystique of randomised 
controlled trials, and I expected howls of protest from 
readers and medical academics – how dared we attack such 
unassailable institutionalised experience!
To my surprise, we did not receive a single protest either in 
writing or by telephone. Now your editorial has vindicated my 
position that the article had value.
Compare a statement by yourself: ‘RCTs are by no means 
always reliable or consistent’, with a statement by Dr Brom: 
‘The controlled clinical trial is dependent on three basic criteria: 
(i) that the two groups being compared are similar; (ii) that the 
individuals in the groups are representative of the population 
that one is trying to investigate; and (iii) if either is suspect, the 
results could be totally wrong and the methodology should not 
be classified as strictly scientific.’
The wheel has turned full circle. Thank you, Professor 
Ncayiyana.
F N Sanders
401 Villa Tiberina
St James Road
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fred.sanders@discoverymail.co.za
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Academic health sectors fail in HIV 
response
To the Editor: The recent StatsSA analysis1 of causes of 
mortality shows that infectious diseases are by some distance 
the biggest killers in South Africa (Fig. 1). The breakdown of 
these figures into death per age category showing the dramatic 
increases in mortality among 20 - 50-year olds, provides a better 
indication of the devastation that the TB/HIV epidemic has 
visited on our social fabric (Fig. 2).
One of the key measures of an effective health sector is its 
responsiveness to the health needs of its people.2 To what 
extent have South African academic and tertiary services been 
responsive to the explosion of the HIV/TB pandemics?
Was the fact that there were no questions asked on HIV/TB 
in recent Fellowship of the College of Physicians Part I papers 
exceptional for this exam? If one looks at past paper Is from 
2001 to 2006 we see that this is far from exceptional (Fig. 3). 
As shown in Fig. 4, questions pertaining to HIV/TB comprise 
2% of the questions asked over this period. (The questions in 
all the FCP Part I papers from 2001 to 2006 were analysed in 
terms of which chapter from Harrison’s Principles of Medicine 
would provide the bulk of the answer. All questions on drug 
management were classified as pharmacology.)  
Unfortunately this under-representation of HIV/TB seems 
to be mirrored in at least some academic institutions. For 
example one of the tertiary hospitals in the Western Cape has 
no consultants and no senior or junior registrars covering 
infectious diseases. While this situation is apparently being 
given top priority for change, the fact that this unit is in such a 
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